Atea Prescribed drugs, Inc. launched its fourth quarter and full-year 2025 monetary outcomes, highlighting progress in its Part 3 persistent hepatitis C virus (HCV) program and enlargement into hepatitis E virus (HEV) remedies.
Monetary Highlights
The corporate reported a web lack of $44.9 million for This autumn 2025, in comparison with $33.5 million within the prior-year interval. Full-year web loss narrowed to $158.3 million from $168.4 million in 2024.
Analysis and growth bills rose to $47.8 million in This autumn, pushed by elevated spending on Part 3 HCV trials, together with comparator drug purchases and a Merck milestone fee. Full-year R&D prices reached $148.0 million, up barely from $144.1 million.
Normal and administrative bills declined to $7.1 million in This autumn from $13.4 million, primarily because of decrease stock-based compensation. Money and investments stood at $301.8 million as of December 31, 2025, down from $454.7 million a yr earlier.
HCV Program Advances Towards 2026 Knowledge Readouts
Atea accomplished enrollment within the North American C-BEYOND Part 3 trial for its bemnifosbuvir (BEM)/ruzasvir (RZR) fixed-dose mixture, involving over 880 sufferers. Topline outcomes are anticipated mid-2026. The worldwide C-FORWARD trial anticipates enrollment completion mid-2026, with information due by year-end.
Part 2 information confirmed the 8-week routine attaining 98% SVR12 within the per-protocol inhabitants and 95% within the efficacy-evaluable group. The routine demonstrates a excessive resistance barrier, low drug-drug interplay danger, no meals impact, and no dose changes for hepatic or renal impairment.
“Our rigorous execution advancing our international Part 3 HCV program… positions our routine uniquely to handle unmet wants,” said Jean-Pierre Sommadossi, PhD, CEO and Founder.
New HEV Candidate AT-587 Set for Medical Trials
Atea chosen AT-587 because the lead for its HEV program after in vitro information confirmed 30-150 occasions higher efficiency than sofosbuvir or ribavirin towards HEV genotypes 1 and three. Medical growth begins mid-2026 post-IND research.
AT-587 additionally reveals exercise towards flaviviruses, rubella, and chikungunya, with excessive liver cell metabolite ranges and no toxicity noticed.
“Within the yr forward, we stay centered on delivering topline outcomes from our international Part 3 HCV program and initiating scientific growth of AT-587,” added Dr. Sommadossi.
Key opinion leaders emphasised the necessity for regimens like BEM/RZR to assist test-and-treat fashions, citing brief period and dosing comfort.
